Advertisement
UK markets closed
  • FTSE 100

    8,143.21
    +64.35 (+0.80%)
     
  • FTSE 250

    19,818.60
    +216.62 (+1.11%)
     
  • AIM

    755.54
    +2.42 (+0.32%)
     
  • GBP/EUR

    1.1663
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.2460
    -0.0051 (-0.41%)
     
  • Bitcoin GBP

    50,977.95
    -77.66 (-0.15%)
     
  • CMC Crypto 200

    1,324.49
    -72.05 (-5.16%)
     
  • S&P 500

    5,096.53
    +48.11 (+0.95%)
     
  • DOW

    38,174.48
    +88.68 (+0.23%)
     
  • CRUDE OIL

    83.93
    +0.36 (+0.43%)
     
  • GOLD FUTURES

    2,344.70
    +2.20 (+0.09%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,162.33
    +245.05 (+1.37%)
     
  • CAC 40

    8,094.69
    +78.04 (+0.97%)
     

How Novartis’s Sandoz Business Performed in Q1

How Novartis’s Sandoz Business Performed in Q1

Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics—products that are difficult to develop and manufacture. Sandoz revenue grew 4% YoY (year-over-year) to ~$2.5 billion in the first quarter. The chart below shows Sandoz’s revenue since Q1 2017.